There are five methods of finding these new uses:

  • Bioinformatics approaches: using mathematical methods of associating drugs to diseases, based on genomic, linguistic or other associative analysis. All such methods need experimental validation
  • Pharmacology models: finding newpathway associations for differentdiseases
  • Screening for different off-target pharmacological activities among existing drugs
  • Clinical experimentation
  • Knowledge based approach, based on existing information and bridging to a new patent-protectable aspect

Numedicus uses the last approach, making use of the database at In our experience, this has proven accurate and reliable.

A typical collaborative project may involve the following components:

  • identification of agreed therapeutic focus
  • presentation of anonymised, preliminary ideas
  • agreement of scope of collaboration and commercial terms
  • identification new therapeutic opportunities
  • validation of ideas through preclinical biological determination
  • delineation of patent strategy and prosecution of patents

As mentioned in the Track Record section, Numedicus has used the therapeutic switching strategy to identify over a dozen preclinical and clinical development projects.